KEGG   DRUG: Teclistamab
Entry
D12177                      Drug                                   
Name
Teclistamab (USAN/INN);
Teclistamab (genetical recombination) (JAN);
Teclistamab-cqyv;
Tecvayli (TN)
Product
Formula
C6383H9847N1695O2003S40
Exact mass
143571.9603
Mol weight
143660.238
Sequence
(Heavy chain)
QLQLQESGPG LVKPSETLSL TCTVSGGSIS SGSYFWGWIR QPPGKGLEWI GSIYYSGITY
YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARH DGAVAGLFDY WGQGTLVTVS
SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEAAGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
GNVFSCSVMH EALHNHYTQK SLSLSLGK
(Light chain)
SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQPPG QAPVVVVYDD SDRPSGIPER
FSGSNSGNTA TLTISRVEAG DEAVYYCQVW DSSSDHVVFG GGTKLTVLGQ PKAAPSVTLF
PPSSEELQAN KATLVCLISD FYPGAVTVAW KGDSSPVKAG VETTTPSKQS NNKYAASSYL
SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
(heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR IRSKYNNYAT
YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR HGNFGNSYVS WFAYWGQGTL
VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFL LYSKLTVDKS
RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK
(light chain)
QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI GGTNKRAPGT
PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF GGGTKLTVLG QPKAAPSVTL
FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
(Disulfide bridge: H22-H97, H135-L213, H148-H204, H227-h231, H230-h234, H262-H322, H368-H426, h22-h98, h139-l214, h152-h208, h266-h326, h372-h430, L22-L87, L136-L195, l22-l90, l137-l196)
  Type
Peptide
Remark
ATC code: L01FX24
Product: D12177<US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
  Type
Monoclonal antibody, bispecific antibody
Comment
Treatment of multiple myeloma
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
CD3E [HSA:916] [KO:K06451]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX24 Teclistamab
      D12177  Teclistamab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Teclistamab
    D12177  Teclistamab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D12177  Teclistamab (USAN/INN) <US>
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3E
     D12177  Teclistamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12177
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12177
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12177
Other DBs
CAS: 2119595-80-9
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system